A multi-centre randomised controlled trial comparing megestrol acetate to levonorgestrel-intrauterine system in fertility sparing treatment of atypical endometrial hyperplasia.
Atypical endometrial hyperplasia
Fertility
Levonorgestrel-intrauterine system
Megestrol acetate
Randomised controlled trial
Journal
Journal of assisted reproduction and genetics
ISSN: 1573-7330
Titre abrégé: J Assist Reprod Genet
Pays: Netherlands
ID NLM: 9206495
Informations de publication
Date de publication:
31 Aug 2024
31 Aug 2024
Historique:
received:
05
04
2024
accepted:
12
06
2024
medline:
1
9
2024
pubmed:
1
9
2024
entrez:
31
8
2024
Statut:
aheadofprint
Résumé
The objective of the trial was to compare the regression rate of atypical endometrial hyperplasia (AEH) in patients treated with megestrol acetate (MA) vs. levonorgestrel-intrauterine device (LNG-IUS). We also aimed to assess the fertility and pregnancy outcomes in these patients. The study was a phase II multi-centre randomised controlled trial on the use of MA compared to LNG-IUS in the treatment of AEH conducted from January 2020 to January 2024 in Singapore. Women who were diagnosed with AEH and between 21 and 40 years old were included. The patients were randomised to receive either MA (160 mg orally daily) or LNG-IUS. The primary outcomes assessed were the regression rates at 3 months, 6 months and 9 months of treatment. The secondary outcomes assessed were the side effects, patient acceptability and fertility outcomes. Thirty-six patients completed the trial. The overall regression rate was 88.9% by 9 months. There was no statistically significant difference in the 9-month complete regression rate between MA vs. LNG-IUS. There was also no significant difference in side effects and weight change between both arms. Nineteen patients were actively pursuing fertility after complete regression. There were 8 pregnancies achieved, with resultant 4 live births and 4 miscarriages. Our study confirms a high regression rate of AH with medical treatment. LNG-IUS is a non-inferior treatment compared to megestrol acetate. Successful pregnancy outcomes can be achieved after regression of AEH. Long-term studies of sufficient sample-size are needed to assess for fertility and pregnancy outcomes, risk of recurrence and long-term risk of malignancy. The study was registered with the Health Science Authority (HSA) (License No.: CTA1900087) on September 5, 2019: https://eservice.hsa.gov.sg/prism/ct_r/enquiry.do?action=loadSpecificDetail . The trial was registered retrospectively on ClinicalTrials.gov (ID: NCT05492487) on April 7, 2022: https://clinicaltrials.gov/study/NCT05492487 .
Identifiants
pubmed: 39215793
doi: 10.1007/s10815-024-03172-z
pii: 10.1007/s10815-024-03172-z
doi:
Banques de données
ClinicalTrials.gov
['NCT05492487']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : SingHealth
ID : AM/CT004/2020
Informations de copyright
© 2024. The Author(s).
Références
Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, Alberts D, Curtin J. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006;106(4):812–9. https://doi.org/10.1002/cncr.21650 .
doi: 10.1002/cncr.21650
pubmed: 16400639
Koskas M, Uzan J, Luton D, Rouzier R, Daraï E. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril. 2014;101(3):785–94. https://doi.org/10.1016/j.fertnstert.2013.11.028 .
doi: 10.1016/j.fertnstert.2013.11.028
pubmed: 24388202
Singapore Cancer Registry Annual Report 2021. Available on: https://www.nrdo.gov.sg/docs/librariesprovider3/default-document-library/scr-ar-2021-web-report.pdf?sfvrsn=591fc02c_0 . Accessed 5 Apr 2024.
Wise MR, Jordan V, Lagas A, Showell M, Wong N, Lensen S, Farquhar CM. Obesity and endometrial hyperplasia and cancer in premenopausal women: a systematic review. Am J Obstet Gynecol. 2016;214(6):689.e1-689.e17. https://doi.org/10.1016/j.ajog.2016.01.175 .
doi: 10.1016/j.ajog.2016.01.175
pubmed: 26829507
Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 2018;110:354–61. https://doi.org/10.1093/jnci/djx214 .
doi: 10.1093/jnci/djx214
pubmed: 29045681
Luo L, Luo B, Zheng Y, Zhang H, Li J, Sidell N. Oral and intrauterine progestogens for atypical endometrial hyperplasia. Cochrane Database Syst Rev. 2018;12(12):009458. https://doi.org/10.1002/14651858.CD009458.pub3 .
doi: 10.1002/14651858.CD009458.pub3
Orbo A, Vereide A, Arnes M, Pettersen I, Straume B. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG. 2014;121(4):477–86. https://doi.org/10.1111/1471-0528.12499 .
doi: 10.1111/1471-0528.12499
pubmed: 24286192
Xu Z, Yang B, Shan W, Liao J, Shao W, Wu P, Zhou S, Ning C, Luo X, Zhu Q, et al. Comparison of the effect of levonorgestrel-intrauterine system with or without oral megestrol acetate on fertility-preserving treatment in patients with atypical endometrial hyperplasia: a prospective, open-label, randomized controlled phase II study. Gynecol Oncol. 2023;174:133–41. https://doi.org/10.1016/j.ygyno.2023.05.001 .
doi: 10.1016/j.ygyno.2023.05.001
pubmed: 37182434
Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010;203(6):547.e1-10. https://doi.org/10.1016/j.ajog.2010.07.037 .
doi: 10.1016/j.ajog.2010.07.037
pubmed: 20934679
Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, et al. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021;224(2):191.e1-191.e15. https://doi.org/10.1016/j.ajog.2020.08.032 .
doi: 10.1016/j.ajog.2020.08.032
pubmed: 32805208
Ring KL, Mills AM, Modesitt SC. Endometrial hyperplasia. Obstet Gynecol. 2022;140(6):1061–75. https://doi.org/10.1097/AOG.0000000000004989 .
doi: 10.1097/AOG.0000000000004989
pubmed: 36357974
Mittermeier T, Farrant C, Wise MR. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database Syst Rev. 2020;9(9):CD012658. https://doi.org/10.1002/14651858.CD012658.pub2 .
doi: 10.1002/14651858.CD012658.pub2
pubmed: 32909630
Management of endometrial intraepithelial neoplasia or atypical endometrial hyperplasia: ACOG Clinical Consensus No. 5. Obstet Gynecol. 2023;142(3):735–744. https://doi.org/10.1097/AOG.0000000000005297 .
Contreras NA, Sabadell J, Verdaguer P, Julià C, Fernández-Montolí ME. Fertility-sparing approaches in atypical endometrial hyperplasia and endometrial cancer patients: current evidence and future directions. Int J Mol Sci. 2022;23(5):2531. https://doi.org/10.3390/ijms23052531.PMID:35269674;PMCID:PMC8910633 .
doi: 10.3390/ijms23052531.PMID:35269674;PMCID:PMC8910633
pubmed: 35269674
pmcid: 8910633
Clement NS, Oliver TR, Shiwani H, Sanner JR, Mulvaney CA, Atiomo W. Metformin for endometrial hyperplasia. Cochrane Database Syst Rev. 2017;10(10):CD012214. https://doi.org/10.1002/14651858.CD012214.pub2 .
doi: 10.1002/14651858.CD012214.pub2
pubmed: 29077194
Fernandez-Montoli ME, Sabadell J, Contreras-Perez NA. Fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer: a Cochrane Systematic Review Protocol. Adv Ther. 2021;38(5):2717–31. https://doi.org/10.1007/s12325-021-01693-y .
doi: 10.1007/s12325-021-01693-y
pubmed: 33830463
De Rocco S, Buca D, Oronzii L, Petrillo M, Fanfani F, Nappi L, Liberati M, D’Antonio F, Scambia G, Leombroni M, et al. Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2022;273:90–7. https://doi.org/10.1016/j.ejogrb.2022.04.019 .
doi: 10.1016/j.ejogrb.2022.04.019
pubmed: 35526471
Inoue O, Hamatani T, Susumu N, Yamagami W, Ogawa S, Takemoto T, Hirasawa A, Banno K, Kuji N, Tanaka M, et al. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia. Reprod Biol Endocrinol. 2016;15(14):2. https://doi.org/10.1186/s12958-015-0136-7.PMID:26769300;PMCID:PMC4714532 .
doi: 10.1186/s12958-015-0136-7.PMID:26769300;PMCID:PMC4714532
Oishi M, Kasuga Y, Fukuma Y, Hamuro A, Tamai J, Tanaka Y, Hasegawa K, Yoshimura T, Ikenoue S, Ochiai D, et al. Obstetric outcomes after medroxyprogesterone acetate treatment for early stage endometrial cancer or atypical endometrial hyperplasia: a single hospital-based study. Int J Clin Oncol. 2023;28(4):587–91. https://doi.org/10.1007/s10147-023-02297-y .
doi: 10.1007/s10147-023-02297-y
pubmed: 36662363
Park JY, Seong SJ, Kim TJ, Kim JW, Bae DS, Nam JH. Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer. Gynecol Oncol. 2017;146(1):39–43. https://doi.org/10.1016/j.ygyno.2017.05.002 .
doi: 10.1016/j.ygyno.2017.05.002
pubmed: 28526167
Yang BY, Gulinazi Y, Du Y, Ning CC, Cheng YL, Shan WW, Luo XZ, Zhang HW, Zhu Q, Ma FH, Liu J, Sun L, Yu M, Guan J, Chen XJ. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. BJOG. 2020;127(7):848–57. https://doi.org/10.1111/1471-0528.16108 .
doi: 10.1111/1471-0528.16108
pubmed: 31961463
Rodolakis A, Scambia G, Planchamp F, Acien M, Di Spiezio Sardo A, Farrugia M, Grynberg M, Pakiz M, Pavlakis K, Vermeulen N, Zannoni G, Zapardiel I. Mmegalon KLT 2023 ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma. Hum Reprod Open. 2023;1:hoac057. https://doi.org/10.1093/hropen/hoac057 .
doi: 10.1093/hropen/hoac057
Zaino RC, Carinelli SG, Ellenson LH, Eng C, Katabuchi H, Konishi I, Lax S. Tumours of the uterine corpus: epithelial tumours and precursors. Lyon: WHOPress; 2014. p. 125–6.